Navigation Links
$1.9 million NIH grant supports research in the most common soft tissue tumor in children
Date:2/20/2011

A nearly $2 million grant from the National Institutes of Health (NIH) will help investigators at Nationwide Children's Hospital search for biomarkers that may be linked to the development and outcome of hemangiomas, the most common soft tissue tumor in children. Nationwide Children's is home to the only Hemangioma and Vascular Malformations Clinic in the United States with an NIH-sponsored clinical study.

A hemangioma is an abnormal buildup of blood vessels in the skin or internal organs. Hemangiomas appear as a red to reddish-purple, raised lesion or as a massive, raised tumor.

"Hemangiomas can be extremely disfiguring and life-threatening, resulting in significant distress for the families of affected children," said the grant's principal investigator, Gayle Gordillo, MD, director of the Hemangioma and Vascular Malformations Clinic in Plastic and Reconstructive Surgery at Nationwide Children's Hospital. "A critical barrier to improving the clinical outcomes for affected children is the lack of low-risk treatment options. The most effective treatment options all have life-threatening side effects."

Dr. Gordillo's laboratory research using a mouse-model has shown that the formation of these soft tissue tumors depends on nox-4. Nox-4 is an enzyme involved in the production of reactive oxygen species, a natural part of a healthy cellular environment. However, excessive production of reactive oxygen species can result in significant damage to the cell.

As part of the NIH-funded study, Dr. Gordillo and colleagues at both Nationwide Children's Hospital and The Ohio State University Medical Center, will examine urine and blood samples from patients with hemangioma beginning from the time they enroll in the study until they are 2 years of age. They will also perform ultrasound on each patient to measure the size of the hemangioma and velocity of the blood flowing to the tumor. Recruitment for study participants will take place at Nationwide Children's.

By comparing samples from these patients with samples from age-matched healthy children, Dr. Gordillo's team will be able to investigate how nox-4 regulates growth of endothelial cells that develop into tumors. They will also search to determine whether biological products caused by nox-4 function can be used as biomarkers to determine patient outcome.

"This is the first prospective, longitudinal study aimed at identifying biomarkers in children with hemangiomas," said Dr. Gordillo, also a faculty member at The Ohio State University College of Medicine. "Our goal is to further understand the role oxidant production has on hemangioma formation. Our findings could help identify potential new treatment targets and establish biomarkers that can be used to design clinical trials to test new therapeutics to treat these soft tissue tumors."


'/>"/>

Contact: Mary Ellen Peacock
MaryEllen.Peacock@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. 3.1 Million Hispanic Americans Struggle With Arthritis
2. 4.7 million Californians to gain coverage under health reform, new study estimates
3. Fossil Suggests Humans Walked Upright 3 Million Years Ago
4. Johns Hopkins School of Medicine grants $5 million to study cognitive disorders
5. Apica Cardiovascular receives $5.1 million investment for improved heart surgery system
6. Researchers predict nearly 1.3 million cancer deaths in Europe in 2011
7. MDA awards $13.5 million in grants for research treatments for neuromuscular diseases
8. U-M Medical School researchers set new record in NIH funding: $368.7 million
9. UofL awarded $9.56 million to form first-ever multicenter cardiovascular research network
10. $2.8 million grant boosts cystic fibrosis research at Queens
11. Cedars-Sinai research team awarded $1.9 million from CIRM to develop new tools and technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: